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To the Editor,A recent JCF article [1] examines the relationship between
sweat chloride, a measure of cystic fibrosis (CF) transmembrane
conductance regulator (CFTR) function, and clinical outcomes
(forced expiratory volume in 1 s [FEV1] andweight) in individuals
with CF and the G551D mutation who participated in clinical
studies of ivacaftor [1]. There is no clear linear correlation
between sweat chloride and FEV1 [1,2]; however, Seliger et al.
declare a threshold-specific predictive relationship between early
sweat chloride values and subsequent clinical measures.
The authors define a threshold for physiologic “success” to be
either a 20 mmol/L reduction or a sweat chloride concentration
≤80 mmol/L at day 15 of the study. They report the positive
predictive value (PPV), or the likelihood of a patient experiencing
a ≥5% improvement in FEV1 at 16 weeks given physiologic
success, as 86.3% among pooled placebo and ivacaftor treatment
groups. The PPVs among the ivacaftor and placebo groups were
88.0% and 33.3%, respectively. While we support the notion that
a marker of CFTR activity such as sweat chloride might be useful
in this regard, a key limitation of the PPV calculation is its
dependency on the outcome prevalence in the study population of
interest; in other words, the higher the prevalence of FEV1
“responders”, the higher the PPV simply due to the statistical
formula used for the calculation [3]. Unfortunately, this prohibits
generalizability to populations where the prevalence of FEV1
improvement may differ. Evaluation of these thresholds in an
independent sample is necessary for PPV validation. Further,
pooling treatment and placebo arms to estimate PPV is
problematic when the prevalence of lung function response is
so different between them (98.9% and 33.7%, respectively). The
interpretation of the pooled PPV is evenmore difficult when large
discrepancies exist between the groups' sensitivity (98.8% and
33.3%) and specificity (0.0% and 96.5%) — indicating that
FEV1 response is predominantly differentiated by treatment
group and not by sweat chloride.
Despite these analytic challenges, we appreciate the authors'
effort to drill beyond simple statistics to better examine a
population level threshold effect. Our intent is not to diminish
the utility of physiologic markers such as sweat chloride in drug
development; however caution must be exercised when
interpreting predictive results from this study design. We are
optimistic that further research and follow-up of patients
treated with ivacaftor or other CFTR modulators will uncover1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.07.002the complex interaction of physiologic markers with clinical
outcomes in CF in the presence of confounding factors such as
airway infection, inflammation, and structural damage.
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